Cases & Deals

XOMA establishes global patent portfolio for IL-1 beta antibodies

Clients XOMA Corporation

Jones Day represents XOMA Corporation for their global patent portfolio for antibodies to IL-1 beta, including gevokizumab, for the treatment of a variety of inflammatory diseases and disorders.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.